
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific has demonstrated significant sales growth across various product lines, with the Watchman device experiencing a 35% year-over-year increase due to strong uptake in concomitant procedures, while the electrophysiology (EP) segment surged by 63%, highlighting successful market share gains. The company is projecting robust organic sales growth of 11-13% for the fourth quarter, alongside expected GAAP EPS in the range of $0.48 to $0.52, underscoring a positive financial outlook. Additionally, promising future revenue streams are anticipated from the Nalu device, expected to surpass $60 million in sales by 2025 and grow at an annual rate exceeding 25% in 2026, further supporting a favorable long-term performance perspective.
Bears say
Boston Scientific faces a challenging outlook primarily due to anticipated foreign exchange headwinds of approximately $0.04 per share, which could impede full-year adjusted earnings. The company's reliance on its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) segments, which operate in mature markets characterized by pricing pressures, may hinder future revenue growth prospects, particularly if there are delays in new product launches. Furthermore, the firm's recent performance highlights mixed growth across various segments, with a significant underperformance in Urology and potential integration issues that could adversely affect operational efficiency and market expectations.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares